Enzon Pharmaceuticals, Inc. financial data

Symbol
ENZN on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
20 Commerce Drive, Suite 135, Cranford, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
ENZON PHARMACEUTICAL INC (to 12/10/2002), ENZON INC (to 12/9/2002)
Latest financial report
10-Q - Q3 2024 - Nov 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 6.08K % -5.25%
Return On Equity 48.3 % +36.9%
Return On Assets 3.22 % +46.3%
Operating Margin -4K % -10.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74.2M shares 0%
Common Stock, Shares, Outstanding 74.2M shares 0%
Entity Public Float 7.59M USD -35.5%
Common Stock, Value, Issued 742K USD 0%
Weighted Average Number of Shares Outstanding, Basic 74.2M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 74.2M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 26K USD
Operating Income (Loss) -1.22M USD -17.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.33M USD +42.8%
Income Tax Expense (Benefit) -195K USD -85.7%
Net Income (Loss) Attributable to Parent 1.52M USD +47.2%
Earnings Per Share, Basic 0 USD/shares -100%
Earnings Per Share, Diluted 0 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 46.6M USD +0.16%
Other Assets, Current 337K USD +2.43%
Assets, Current 47M USD +0.18%
Deferred Income Tax Assets, Net 306K USD +176%
Assets 47.3M USD +0.59%
Accounts Payable, Current 331K USD -1.78%
Accrued Liabilities, Current 107K USD +55.1%
Liabilities, Current 438K USD +7.88%
Retained Earnings (Accumulated Deficit) -69.8M USD +2.13%
Stockholders' Equity Attributable to Parent 2.76M USD +9.82%
Liabilities and Equity 47.3M USD +0.59%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 251K USD +47.6%
Net Cash Provided by (Used in) Financing Activities -1.28M USD 0%
Common Stock, Shares Authorized 170M shares 0%
Common Stock, Shares, Issued 74.2M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.02M USD +7.33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 46.6M USD +0.16%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 34.1M USD -5.9%
Deferred Tax Assets, Gross 34.4M USD -5.44%
Deferred Income Tax Expense (Benefit) -196K USD -34.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2.96M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%